Skip to main content
Clinical Trials/CTRI/2021/01/030193
CTRI/2021/01/030193Not yet recruitingPhase 3

Efficacy of Ayurvedic Multi Drug Therapy along with Erandamooladi Basti in the Management of Chronic Kidney Disease-An Open Labelled Randomized Controlled Clinical Trial

IPGT and RA0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Patients having signs and symptoms of chronic kidney disease.
  • 2.Patients of both genders between 18-60yrs of age.
  • 3.Patients willing and able to participate.
  • 4.Patients with serum creatinine level between1.2- 6 mg/dl will be included in the study.
  • 5.Patients with serum urea level with in 120mg/dl
  • 6.Patients who are yogya for basti karma.

Exclusion Criteria

  • 1.Female patients having pregnancy, breast feeding or post-delivery period.
  • 2.Patients of end stage renal failure.
  • 3.Patients who are on dialysis treatment for more than 1-month period.
  • 4.Patients who are already operated for renal transplantation and then having nephropathy.
  • 5.Patients of hepato-renal insufficiency or renal insufficiency due to hemodynamic circulatory disorders and CCF.
  • 6.Patients having some serious illness like cardio-vascular diseases, acute mental disorders, serious acute organic diseases, serious chronic co-morbidity, hypo or hyper thyroidism.
  • 7.Patients having haemoglobin concentration below 8gm.
  • 8.Having uncontrolled Hypertension(systolic <180mm/Hg, diastolic <100mm/Hg) and Diabetes mellitus (FBS- <200mg/dl)
  • 9.Patients with serum urea level above 120mg/dl
  • 10.Patients having symptoms of Uremia.

Investigators

Sponsor
IPGT and RA

Similar Trials